US OptionsDetailed Quotes

GERN250117C500

Watchlist

3.65
0.000.00%

15min DelayClose Dec 27 16:00 ET

0.00High0.00Low

Geron Stock Discussion

Trytosaveabit

Dec 13 05:51

Update

$Geron (GERN.US)$ Geron Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval Of RYTELO (Imetelstat) For Treatment Of Adult Patients With Transfusion-dependent (TD) Anemia Due To Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes
Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treat...

Trytosaveabit

Dec 10 08:03

Update

$Geron (GERN.US)$ Reuters
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis

Tonyco

Nov 17 17:09

$Geron (GERN.US)$
Almost low enough

Trytosaveabit

Nov 7 06:27

A bit more

$Geron (GERN.US)$ Reuters· 2 mins ago
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available

Trytosaveabit

Nov 7 06:13

News

$Geron (GERN.US)$ Reuters· 1 mins ago
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million

Trytosaveabit

Nov 7 06:05

Some

$Geron (GERN.US)$ Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt

$Geron (GERN.US)$ 🤔

$Geron (GERN.US)$ Really wants to just chill at 4

generous Llama_6844

Oct 17 08:18

Time to dips from the support line , target 4.7 , 10% -15% ROI

$Geron (GERN.US)$ $Geron (GERN.US)$

Trung Luong

Sep 2 13:48

$Geron (GERN.US)$ For those who is new to this company, here is a summary: JNJ paid 250M a year to co develop the drug 5 years ago. They didn’t want to continue the second year which the price was low 5 n drop to lowest of 1.30 in the next 2 years. Gern continue to drug development with the 250M from JNJ to get it FDA approval few months ago to which they raised 450M for reserve cash. The stock went up to hitting 52 weeks high of 5.34 in the next month or two of FDA approval. You now are caught...

No comment yet